EXEL

Exelixis Inc

• TipRanks·14h ago

  Exelixis (EXEL) Gets a Hold from RBC Capital

• Simply Wall St·2d ago

  Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)?

• Seeking Alpha·6d ago

  Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports

• TipRanks·04/02 10:57

  Wells Fargo Sticks to Its Hold Rating for Exelixis (EXEL)

• Reuters·04/01 05:07

  Genmab names Margarida Duarte general manager for Europe and emerging markets

• The Motley Fool·03/31 23:20

  Exelixis: A Strong Contender in the Cancer Drug Market

• TipRanks·03/25 13:37

  Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)

• TipRanks·03/25 12:06

  Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer

• Reuters·03/25 11:59

  Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years

• The Motley Fool·03/18 12:50

  The Best Healthcare Stocks to Buy With $50 Right Now

• Seeking Alpha·03/17 09:12

  PJP: Healthcare Dashboard For March

• Simply Wall St·03/15 00:30

  How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors

• Simply Wall St·03/13 10:25

  Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts

• TipRanks·03/09 10:50

  Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)

• Simply Wall St·03/04 16:31

  A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline